Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

Data Shows AUG-3387 Neutralizes SARS-CoV-2 Delta Variant in Infective Assays Supports Earlier Data Showing AUG-3387 Binds Strongly to Delta Variant in Addition to Wild-Type Spike Protein and Other Variants of Concern Catalent Selected as Contract Drug Manufacturing Organization (CDMO) for AUG-3387 Scale-up Manufacturing for AUG-3387 Proceeding Rapidly; Early Batches Show Promising Results

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

2 COMMENTS

Cancel reply

Please enter your comment!
Please enter your name here